Current Liabilities decreased faster than Adicet Bio Inc 's Cash & cash equivalent, this led to improvement in Adicet Bio Inc 's Quick Ratio to 7.52, above Adicet Bio Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 143 other companies have achieved higher Quick Ratio than Adicet Bio Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 315 to 526.

Explain Quick Ratio?
How much Cash & cash equivalents ACET�s has?
What are ACET�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ACET Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	11.25 %	11.03 %	-2.34 %	-4.61 %	-5.81 %
Y / Y Cash & cash equivalent Change	-8.54 %	-10.08 %	-48.98 %	-44.23 %	-5.81 %
Quick Ratio MRQ	7.52	7.36	5.44	7.32	9.15
ACET's Total Ranking	# 526	# 315	# 522	# 348	# 276
Seq. Current Liabilities Change	-15.02 %	13.67 %	10.9 %	3.84 %	-15.19 %
Seq. Cash & cash equivalent Change	-13.21 %	53.77 %	-17.5 %	-16.93 %	-14.67 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 144
Healthcare Sector	# 220
Overall Market	# 526

Quick Ratio Statistics
High	Average	Low
26.72	4.85	0.08
(Mar 31 2022)		(Dec 31 2018)

Financial Statements
Adicet Bio Inc 's Current Liabilities	$ 18 Millions	Visit ACET's Balance sheet
Adicet Bio Inc 's Cash & cash equivalent	$ 138 Millions	Visit ACET's Balance sheet
Source of ACET's Sales		Visit ACET's Sales by Geography

Cumulative Adicet Bio Inc 's Quick Ratio

ACET's Quick Ratio for the trailling 12 Months

ACET Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	3.71 %	-0.21 %	-2.95 %	-2.83 %	-2.94 %
Y / Y Cash & cash equivalent TTM Growth	-30.38 %	-29.54 %	-25.59 %	-10.04 %	6.32 %
Quick Ratio TTM	6.91	7.26	7.72	9.04	10.29
Total Ranking TTM	# 3520	# 2213	# 2216	# 1592	# 2819
Seq. Current Liabilities TTM Growth	2.5 %	2.98 %	-0.63 %	-1.13 %	-1.37 %
Seq. Cash & cash equivalent TTM Growth	-2.39 %	-3.2 %	-15.14 %	-13.16 %	-1.22 %

Quick ratio ranking by company, industry and sector >> Back to ACET Financial Strength Comparisons >> Go to Compare ACET Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q1 2026 to $18.30 millions, cumulative Quick Ratio decreased to 6.91 above the ACET average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 418 other companies have achieved higher Quick Ratio than Adicet Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2213 to 3520.

Explain Quick Ratio?
How much Cash & cash equivalents ACET�s has?
What are ACET�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 419
Healthcare Sector	# 852
Within the Market	# 3520

trailing twelve months Quick Ratio Statistics
High	Average	Low
18.21	4.8	0.17
(Sep 30 2022)		(Dec 31 2018)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Stoke Therapeutics Inc	20.32	$ 343.545 Millions	$ 16.905 Millions
Liquidia Corporation	20.29	$ 222.786 Millions	$ 10.981 Millions
Vyne Therapeutics Inc	20.17	$ 24.928 Millions	$ 1.236 Millions
Alto Neuroscience Inc	20.11	$ 263.762 Millions	$ 13.115 Millions
Evommune Inc	19.94	$ 211.464 Millions	$ 10.603 Millions
Tyra Biosciences Inc	19.91	$ 383.466 Millions	$ 19.256 Millions
Sagimet Biosciences inc	19.88	$ 104.539 Millions	$ 5.258 Millions
Corvus Pharmaceuticals Inc	19.55	$ 236.714 Millions	$ 12.110 Millions
Ligand Pharmaceuticals Incorporated	19.17	$ 779.405 Millions	$ 40.667 Millions
Dyne Therapeutics Inc	18.97	$ 972.156 Millions	$ 51.249 Millions
Agios Pharmaceuticals Inc	18.41	$ 737.038 Millions	$ 40.040 Millions
Crinetics Pharmaceuticals Inc	18.17	$ 1,291.306 Millions	$ 71.086 Millions
Relmada Therapeutics Inc	18.15	$ 233.963 Millions	$ 12.892 Millions
Phio Pharmaceuticals Corp	17.93	$ 17.031 Millions	$ 0.950 Millions
Amylyx Pharmaceuticals Inc	17.52	$ 279.768 Millions	$ 15.966 Millions
Minerva Neurosciences Inc	17.42	$ 78.065 Millions	$ 4.482 Millions
Lexicon Pharmaceuticals Inc	17.24	$ 170.658 Millions	$ 9.898 Millions
Sellas Life Sciences Group Inc	16.60	$ 107.197 Millions	$ 6.456 Millions
Pliant Therapeutics Inc	16.50	$ 170.892 Millions	$ 10.359 Millions
Innoviva Inc	16.50	$ 603.085 Millions	$ 36.558 Millions
Dianthus Therapeutics Inc	16.29	$ 617.109 Millions	$ 37.884 Millions
Janux Therapeutics Inc	16.23	$ 956.386 Millions	$ 58.915 Millions
Praxis Precision Medicines Inc	16.12	$ 786.865 Millions	$ 48.806 Millions
Nuvalent Inc	15.88	$ 1,287.476 Millions	$ 81.051 Millions
Oric Pharmaceuticals Inc	15.86	$ 281.932 Millions	$ 17.771 Millions
Adc Therapeutics Sa	15.86	$ 231.008 Millions	$ 14.567 Millions
Protagonist Therapeutics inc	15.86	$ 547.786 Millions	$ 34.549 Millions
Aprea Therapeutics Inc	15.80	$ 46.466 Millions	$ 2.941 Millions
Emmis Acquisition Corp	15.64	$ 0.782 Millions	$ 0.050 Millions
Rezolute Inc	15.61	$ 120.268 Millions	$ 7.704 Millions

Date modified: 2026-09-08T15:11:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.